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Introduction
Human  MGP  gene  is  located  at  12p13.1–p12.3  and  con-
sists  of  four  exons  which  codes  for  a  10-kDa  Matrix  Gla 
(-carboxyglutamic acid) protein, containing five residues 
of  the  vitamin  K-dependent  calcium  binding  amino  acid 
-carboxyglutamic acid (Gla). (Price et al. 1983, 2000; Price 
and Williamson 1985; Shanahan et al. 1998; Afshin et al. 
2001). MGP was first isolated from the matrix of bone, but is 
now known to be synthesized in all tissues tested, with the 
highest levels of synthesis in heart, kidney, lung, and carti-
lage (Luo et al. 1997; Price et al. 2000). MGP is a member of 
the family of extracellular mineral-binding Gla proteins, with 
high accumulation in bone and cartilage (Paul et al. 2002). 
All  currently  available  scientific  evidence  indicates  that 
MGP plays a significant role as an inhibitor of mineralization 
(Price et al. 1983, 2000; Shanahan et al. 1998; Afshin et al. 
2001).  The  accumulation  of  MGP  protein  in  mineralized 
bone  and  calcified  cartilage  could  be  due  to  its  calcium 
binding properties related to the presence of carboxylated 
residues and greatly exceeds that of the soft tissues, which 
fail to accumulate MGP under normal conditions but can do 
so when subjected to abnormal mineralization (Price et al. 
2000; Afshin et al. 2001).
Cancela et al. (1990) cloned a human genomic library 
using an MGP cDNA probe and found that the gene spans 
3.9 kb.  Each  exon  of  MGP  corresponds  to  the  domains 
found in all known vitamin K dependent vertebrate pro-
teins: a transmembrane signal peptide, followed by putative 
  gamma-carboxylation recognition site, and a Gla-containing 
domain (Luo et al. 1997; Afshin et al. 2001). MGP contains a 
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abstract
Matrix γ-carboxy glutamic acid protein (MGP) is a 10-kDa secreted protein containing five residues of the vitamin 
K-dependent calcium binding amino acid γ-carboxyglutamic acid (Gla). This study was carried out to examine the 
effects of MGP gene promoter polymorphism (T-138C) on blood lead levels (BLL) and hematological parameters 
in 113 battery manufacturing unit workers occupationally exposed to lead and 102 controls. Genotypes for the 
MGP T-138C polymorphism were determined by PCR and restriction fragment length digestion. BLL were deter-
mined by Anode Stripping Voltammetry using ESA Model 3010B Lead analyzer. Complete blood picture (CBP) 
was analyzed using ADVIA Cell counter for each sample. The frequencies of MGP–TT, CT and CC genotypes in our 
population were 38.6%, 44.3%, and 17.2%, respectively. The frequencies for T and C alleles were 0.612 and 0.386, 
respectively. Although BLL did not differ significantly among genotypes; they were higher in workers with TT/CT 
genotype compared to CC genotype subjects (76–88 μg/dL vs 22–45 μg/dL, p > 0.05). About 29.2% of volunteers 
(n = 33) from the occupationally exposed group had hemoglobin levels below 10.0 gms/dl. There was no signifi-
cant difference in total white cell count and platelet count between occupational and non-exposed groups. The 
possible role of SNPs in the promoter region of MGP gene with relation to lead toxicity was investigated for the 
first time in the Indian population; although significance could not be achieved in this study, further assessments 
over a larger population size may help in better understanding of the consequences of lead exposure.
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fourth exon of unknown function that codes for 11 residues 
and lies between the transmembrane signal peptide and the 
putative recognition site for the gamma-carboxylase (Price 
et al. 2000; Afshin et al. 2001). This 4-exon organization is 
essentially identical to that of bone Gla protein and is quite 
different from the 2-exon organization encoding this region 
in the other known vitamin K-dependent proteins.
Due to the numerous molecular and biochemical effects 
of lead in adults, children, and infants, understanding the 
mechanisms of lead toxicity still remains as a major chal-
lenge to researchers (Ellenhorn 1997; ATSDR 1998; Bergdahl 
1998). Lead exposure has been associated with increased 
risk of lung, stomach, and bladder cancer in diverse human 
populations (Fu and Boffetta 1995; Steenland and Boffetta 
2000; NTP 2003). Studies have demonstrated lead induced 
genotoxicity in vitro using cultured human peripheral blood 
lymphocytes (Shaik et al. 2006).
MGP gene suppresses calcium ion function in the car-
tilage, and other soft tissues, in addition, lead and calcium 
are divalent cations, having the same absorption pathways 
(Goyer 2001). Therefore, Pb2+ ions can compete with Ca2+; the 
influence of MGP polymorphism with respect to lead depo-
sition assumes importance in understanding the molecular 
basis of lead toxicity. The main objective of this study was, 
thus, to explore the relationship between polymorphisms in 
the promoter region of MGP gene and investigate its prob-
able association with lead poisoning. The study also assesses 
the influence of MGP genotypes in the study group with rela-
tion to certain hematological parameters like CBP and BLL.
Materials and methods
Sample collection and preparation
Two  hundred  and  fifteen  volunteers  (total  198  men  and 
27 women) aged from 18 to 51 years living in the city of 
Hyderabad (Andhra Pradesh, India) were enrolled in this 
study.  One  hundred  and  thirteen  subjects  were  working 
occupationally in the lead battery industry. Only subjects 
reporting at least two of the symptoms of lead toxicity like 
headache, nausea, gastritis, vomiting, lethargy, and poor 
appetite were enrolled in the study. One hundred and two 
volunteers  not-exposed  occupationally  to  lead  formed 
the controls. This study was approved by the Institutional 
Review Board and Ethics Committee, and each subject pro-
vided written informed consent. Details of previous medi-
cal history, present health status, nutritional status, years 
of exposure, and duration of working hours were recorded. 
Five  milliliters  of  venous  blood  samples  were  collected 
from  each  volunteer  in  two  tubes,  one  with  heparin  for 
metal analysis, and one containing EDTA for hematological 
evaluations.
Determining hematological parameters
Complete  blood  picture  (CBP)  was  determined  using 
ADVIA  Cell  counter  for  each  sample.  This  included 
Hemoglobin, platelet count, total WBC count, Total RBC 
count, PCV, and MCV.
Blood lead level estimation
For the estimation of BLL, ESA Model 3010B Lead analyzer 
was used, which determines the level of lead in blood by 
anode  stripping  voltammetry  (ASV).  The  fundamental 
principle of operation is when a sufficiently large negative 
potential is placed on an electrode, lead ions in solution are 
plated on a mercury electrode. After a fixed plating time, 
the potential is made less negative to strip the metal off the 
electrode. The observed current during the stripping proc-
ess is integrated, and is directly proportional to the con-
centration of the lead in the sample. The concentrations of 
the calibrators provided by ESA are determined with refer-
ence to standards from NIST and CDC. All the precautions 
were  taken  while  sampling  and  processing  to  avoid  lead 
contamination.  Estimations  of  BLLs  were  performed  at 
Secunderabad Diagnostic Center (Hyderabad, A.P), which 
is accredited by the National Accreditation Board for Testing 
and Calibration Laboratories (NABL) for following ISO/IEC 
17025 Standards.
Genotype determination for the MGP gene polymorphism
Polymerase  chain  reaction  (PCR)  is  a  technique  widely 
used in molecular biology to amplify a piece of DNA by 
in vitro enzymatic replication using stable DNA polymer-
ase. As PCR progresses, the DNA template is exponentially 
amplified across several orders of magnitude, generating 
multiple copies of the DNA fragment of interest. An assay 
based  on  polymerase  chain  reaction  (PCR)–Restriction 
fragment length polymorphism (RFLP) was used to deter-
mine the genotype of the MGP gene, as described previ-
ously (Zhang et al. 2003). PCR was performed in a 50 l 
reaction  volume  containing  0.5 M  of  each  primer  was 
used, as below.
Sense primer:  •	
5’-AAGCATACGATGGCCAAAACTTCTGCA-3’
Antisense primer:  •	
5’-GAACTAGCATTGGAACTTTTCCCAACC-3’
The amplification reaction was done using 200 M of each 
dNTP, 10X PCR buffer supplied by Bangalore Genei, 2.5 mM 
MgCl2, and 3U Taq DNA polymerase. The running conditions 
were pre-denaturation at 94°C for 5 minutes, followed by 35 
cycles of denaturation at 94°C for 30 seconds, annealing at 
60°C for 30 seconds, and synthesis at 72°C for 1 minute. Final 
extension was conducted at 72°C for 5 minutes. The ampli-
fied products were digested overnight with BsrI at 65°C and 
the  fragments  were  separated  by  electrophoresis  in  12% 
polyacrylamide gel, and visualized by silver staining. The 
TT genotype is characterized by a 118 bp band, CT genotype 
(118 & 142 bp bands) and CC genotype (142 bp band).
Statistical analyses for polymorphism detection
Chi-square  analysis  was  used  to  determine  whether  the 
genotype distribution was in Hardy-Weinberg equilibrium 
and to compare distributions of alleles and genotypes in the 
different groups of subjects (Zar 1996). P-value was analyzed MGP gene polymorphisms and lead toxicity    211
for the significance. Statistical analyses were performed with 
the MedCalc statistical program.
Results
Table 1 summarizes the basic characteristics of the study 
subjects.  During  the  time  of  presentation,  12  of  the  113 
occupationally  exposed  volunteers  reporting  symptoms 
of  lead  toxicity  appeared  severely  malnourished.  Blood 
samples  collected  from  all  volunteers  were  analyzed  for 
CBP and only the parameters related to anemic conditions 
like  hemoglobin  are  presented  here.  This  is  because  the 
hemoglobin levels showed a very wide range of variation, 
as represented in Table 2. Hemoglobin levels of occupa-
tional  workers  ranged  between  7.0–14.0 gms/dl,  whereas 
Hb levels in unexposed workers was 11.3–14.8 gms/dl. It 
was observed that 33 subjects from the exposed group had 
low Hb levels (below 10 gms/dl) compared to the controls. 
Packed cell volume (PCV) levels ranged from 28–37%; there 
was no significant difference in total white cell count and 
platelet  count  between  occupational  and  non-exposed 
groups. The Genotype frequencies of MGP–TT, CT, and CC 
were 38.6%, 44.3%, and 17.2%, respectively. The distribu-
tion  of  genotypes  was  in  Hardy-Weinberg  equilibrium. 
Similarly, the allele frequencies for T and C alleles were 
0.612 and 0.386, respectively. BLL did not differ significantly 
among genotypes; however, subjects with TT+CT genotypes 
showed higher BLL than those with mutated homozygotes 
CC (76–88 g/dL vs 22–45 g/dL, p  > 0.05). Blood lead lev-
els of occupationally exposed individuals were much higher 
compared to the non-exposed group (Table 3). Twelve of 33 
exposed subjects were malnourished, and severely anemic 
with hemoglobin levels below 10 gmd/dl. These data indi-
cate  that  of  the  113  occupationally  exposed  individuals, 
the MGP CC subjects (n = 17) showed a hemoglobin range 
of 7.0–13.4 gms and a BLL of up to 88 µg/dl. The MGP TT/
CT  individuals  (n  =  96)  showed  a  hemoglobin  range  of 
10.1–14.2 gm% and a BLL within a range of 22–45 µg/dl. In 
the control group, the MGP CC (n = 20) subjects showed a 
BLL of 3.4 µg/dl and hemoglobin level up to 14.8 gms/dl, 
respectively. The MGP TT/CT individuals (n = 82) showed 
a hemoglobin of 11.2–14.0 gms/dL and a BLL of 2 µg/dl). 
There was no significant difference in total white cell count 
and platelet count between occupational and non-exposed 
lead-exposed groups.
Discussion
Genetic association studies with candidate genes are widely 
used to study complex diseases caused by epigenetic factors 
(Cardon and Bell 2001). This study aims to identify the rela-
tion of some SNPs with emphasis on lead toxicity. Since MGP 
gene is an important biomarker associated with atheroscle-
rotic calcification and involved in calcium metabolism; it 
can be hypothesized that it may also be associated with lead 
toxicity. Therefore, this study tries to correlate the influence 
of MGP promoter gene polymorphisms with BLL in a group 
of battery manufacturers who are occupationally exposed to 
lead. Blood lead level (g/dl) is the biologic index most often 
used by health care providers as an indicator of recent lead 
exposure (Astrin et al. 1987; Bressler and Goldstein 1991). As 
lead interrupts the heme synthesis it was essential to inves-
tigate the hematological parameters (CBP) of all individuals 
(both exposed and controls).
Studies by Paul et al. (2002) on rats to evaluate the func-
tion of MGP in bone metabolism indicate an elevation in 
Table 1.  Characteristics of the study group (n = 225).
Parameters Range of exposed Non-exposed
Age range 18–51 years 18–51 years
Sex 100 men and 13 women 
(total 113)




4–10 years Not exposed
Alcohol consumption 31 frequently and  
8 occasionally
nil
Smoking and tobacco 
chewing
40 9
Medical history Most of them complained 
about symptoms like  
gastritis and headache
nil
Table 2.  Hemoglobin ranges of the study group (occupationally exposed 
and controls) along with normal ranges.
S.No Range of Hb (gm/dl)
No. of subjects
Exposed Control
1 7.0–8.0  5 —
2 8.1–9.0  9 —
3 9.1–10.0 19 —
4 10.1–11.0 39 —
5 11.1–12.0 22 44
6 12.1–13.0 13 37
7 13.1–14.0  6 21
Total   113 102
Number  of  highly  anemic  individuals  in  the  exposed  group  was  33. 
Twelve malnourished volunteers were among these 33 highly anemic 
individuals.
Normal ranges: Hb: Males 13.5–18.0 gms/dl, Females 11.5–16.5 gms/dl;   
PCV:  Males  40–54%,  Females  37–47%;  WBC:  4,000–11,000  cells/mcl; 
Platelets: 1.5–5 lakhs/cumm.
Table 3.  Variations of blood lead levels and hemoglobin levels in MGP TT/CT and CC individuals.
S.No Subjects Polymorphism Hb (gm%) BLL (g/dl)
1 Occupationally exposed individuals (n = 113) MGP (TT/CT) (n = 96) 10.1–14.2 76–88
MGP (CC) (n = 17) 7.0–13.4 21.8–45
2 Control group (n = 102) MGP (TT/CT) (n = 82) 11.2–14.0 0.6–3.4
MGP (CC) (n = 20) 11.3–14.8 1.0–1.9
p > 0.05.212    Abjal Pasha Shaik and Kaiser Jamil
serum levels of MGP after etidronate injections and its strong 
binding to bone mineral, thus inhibiting abnormal calcifi-
cation of arteries and other soft tissues. Recent genetic and 
biochemical studies have established MGP as the first pro-
tein known to act as a calcification inhibitor in vivo (Speer 
and Giachelli 2004). The ability of MGP to bind with great 
avidity to the mineral complex suggests that MGP is a strong 
inhibitor of crystal growth. Afshin et al. (2001) discovered 
that MGP gene starts with the T-138C polymorphism which 
influences gene expression level; CC genotype MGP show-
ing the highest levels in blood serum followed by CT and TT. 
The C genotype (CT+CC) tended to show a higher calcifica-
tion factor than the TT genotype. Extrapolating from these 
studies indicate that MGP might form soluble complexes 
with the metallic ions, which may be discharged easily by 
the biological system in vitro. Compared with the CC geno-
type, the TT genotype does not favor the lead to discharge, 
causing the storing up of lead. Therefore, BLL of TT geno-
type was found to be higher than the CC genotype. Presence 
of polymorphism in MGP gene may alter the levels of lead 
in the skeleton and soft tissue which causes storing up of 
lead in reverse proportion to MGP level. Considering the 
central role of MGP in vascular calcification and a similar 
pathogenesis  between  vascular  calcification  and  kidney 
stones, we hypothesized that MGP genetic polymorphisms 
may influence the risk of lead toxicity.
To our knowledge, this is the first study describing signifi-
cant effects of the MGP T-138C polymorphism on BLL and 
hematological parameters in battery-exposed workers form 
Hyderabad (A.P., India). The frequency of MGP CC genotype 
was  low  in  our  study  group.  Previously,  an  investigation 
was performed in a Chinese Han population in children by 
Zhang et al. (2003), who showed significant effect of MGP 
gene polymorphisms with BLL.
Further  studies  are  necessary  in  larger  population 
samples  to  demonstrate  the  exact  involvement  of  MGP 
gene in the etiology of lead poisoning. In addition to MGP, 
polymorphisms  in  many  other  genes  like  ALAD,  VDR, 
PBG Synthase, etc., may affect the susceptibility to lead 
exposure.  Rezende  et  al.  (2008)  showed  lower  plasma 
lead, blood lead, and their ratio in subjects with haplotype 
polymorphisms,  suggesting  that  VDR  haplotypes  modu-
late the circulating levels of lead in exposed subjects. The 
role of hemochromatosis gene in the absorption of lead 
and symptoms of lead toxicity are also being increasingly 
examined  (Onalaja  and  Claudio  2000).  In  our  analysis 
of  T-138C  MGP  polymorphism  among  worker  individu-
als  with  TT/CT  genotypes  showed  higher  BLL  (above   
70 µg/dl). Polymorphism of T-138C may have influenced 
the  promoter  region  leading  to  altered  protein  function 
during transcription (Afshin et al. 2001). The highest BLLs 
in our sub-population were seen in TT genotype individu-
als followed by CT and CC genotypes. In our study, subjects 
from the occupational group had lower hemoglobin levels 
(below 10 gms/dl) than the unexposed group, and there was 
no significant difference between subtypes of MGP geno-
type with relation to their hemoglobin levels. There was a 
decrease in hemoglobin levels of malnourished   volunteers 
who were among the 33 highly anemic individuals. Packed 
cell volume (PCV) levels ranged from 28–37% which was 
low compared to normal levels. Improved iron nutrition has 
been found to be important in the reduction and mitigating 
the effects of occupational and environmental exposure to 
lead (Mahaffey 1995; Shaik et al. 2006).
However, in the population that we have studied, although 
levels of lead were varying with respect to polymorphism, sig-
nificance could not be achieved. This may be because of the 
sample size; therefore, higher sample size may be required to 
establish the role of MGP gene SNPs in lead toxicity. Further 
studies on clinical implications of such high exposures in 
both genotype individuals on a larger population size may 
throw more insight with respect to analyses of lead toxicity.
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